Thrasos Therapeutics (Canada), a clinical-stage pharma company focused on acute kidney injury, closed a $35M Series C financing. Participants include SR One, GSK Canada Life Sciences Innovation Fund, Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures.

___________

Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem

Request Account Access HERE